Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner by Madsen, Ralitsa et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncogenic PIK3CA promotes cellular stemness in an allele dose-
dependent manner
Citation for published version:
Madsen, R, Knox, R, Pearce, W, Lopez, S, McGranahan, N, Mahler-Araujo, B, Vanhaesebroeck, B &
Semple, R 2019, 'Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner'
Proceedings of the National Academy of Sciences of the United States of America. DOI:
10.1073/pnas.1821093116
Digital Object Identifier (DOI):
10.1073/pnas.1821093116
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Proceedings of the National Academy of Sciences of the United States of America
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 21. Jun. 2019
Oncogenic PIK3CA promotes cellular stemness in an
allele dose-dependent manner
Ralitsa R. Madsena,b,c, Rachel G. Knoxa,b, Wayne Pearced, Saioa Lopeze,f, Betania Mahler-Araujoa,g,
Nicholas McGranahane,f, Bart Vanhaesebroeckd, and Robert K. Semplea,b,c,1
aMetabolic Research Laboratories, Wellcome Trust–Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ,
United Kingdom; bNational Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, United Kingdom; cCentre for
Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom; dUniversity College London
Cancer Institute, University College London, London WC1E 6DD, United Kingdom; eCancer Research UK Lung Cancer Centre of Excellence, University College
London Cancer Institute, University College London, London WC1E 6DD, United Kingdom; fCancer Genome Evolution Research Group, University College
London Cancer Institute, University College London, London WC1E 6DD, United Kingdom; and gHistopathology Department, Cambridge University
Hospitals National Health Service Foundation Trust, Cambridge CB2 0QQ, United Kingdom
Edited by Frank McCormick, University of California, San Francisco, CA, and approved March 7, 2019 (received for review December 11, 2018)
The PIK3CA gene, which encodes the p110α catalytic subunit of
PI3 kinase (PI3K), is mutationally activated in cancer and in over-
growth disorders known as PIK3CA-related overgrowth spectrum
(PROS). To determine the consequences of genetic PIK3CA activa-
tion in a developmental context of relevance to both PROS and
cancer, we engineered isogenic human induced pluripotent stem
cells (iPSCs) with heterozygous or homozygous knockin of PIK3CAH1047R.
While heterozygous iPSCs remained largely similar to wild-type
cells, homozygosity for PIK3CAH1047R caused widespread, cancer-like
transcriptional remodeling, partial loss of epithelial morphology, up-
regulation of stemness markers, and impaired differentiation to all
three germ layers in vitro and in vivo. Genetic analysis of PIK3CA-
associated cancers revealed that 64% had multiple oncogenic PIK3CA
copies (39%) or additional PI3K signaling pathway-activating “hits”
(25%). This contrasts with the prevailing view that PIK3CAmutations
occur heterozygously in cancer. Our findings suggest that a PI3K ac-
tivity threshold determines pathological consequences of oncogenic
PIK3CA activation and provide insight into the specific role of this
pathway in human pluripotent stem cells.
PI3K | cancer | genetics | pluripotent stem cells | PROS
Class IA phosphoinositide 3-kinases (PI3Ks) are essentialcomponents of the intracellular signaling cascades triggered
by multiple growth factors, especially those acting via cell
membrane receptor tyrosine kinases. Prominent among these are
the insulin and insulin-like growth factor receptors. PI3K sig-
naling is coupled to downstream activation of AKT and mam-
malian target of rapamycin complex 1 (mTORC1), which play
key roles in organismal growth and development (1–3).
Strongly kinase-activating mutations in PIK3CA, the gene
encoding the catalytic p110α subunit of PI3K, are among the most
frequently observed oncogenic events in a range of human tumors
(4). Although widely referred to as cancer “drivers,” the same
mutations have also been identified in nonmalignant, albeit often
severe, overgrowth disorders (5). These disorders are caused by
postzygotic mosaic PIK3CA mutations and are phenotypically di-
verse, reflecting different patterns of mutation distribution and
likely also different strengths of PI3K activation.
The commonest PIK3CA “hot-spot” variant, H1047R, has
been studied extensively in cancer models, both in cells and in
vivo. Endogenous, heterozygous expression in mice seemingly
only results in cancer development in combination with addi-
tional oncogenic drivers (6–11), while transgenic overexpression
of this PIK3CA mutant does lead to early malignancy (12–17). In
cultured cells, PIK3CAH1047R overexpression, but not heterozygous
expression from the endogenous locus, leads to cellular trans-
formation (18, 19). In human tumors, PIK3CA mutations are not
mutually exclusive with other oncogenic alterations within the
PI3K pathway (20), suggesting that stronger pathway activation
may be required for malignant progression. This is supported by
the benign nature of the overgrowth in PIK3CA-related over-
growth spectrum (PROS) where PIK3CAH1047R heterozygosity is
not sufficient to cause cancer. Despite this circumstantial evidence
of dose-dependent effects of genetic PI3K activation, this has not
been examined directly owing to the paucity of isogenic experi-
mental models with endogenous expression of a defined number
of oncogenic variants.
Disorders such as PROS illustrate that understanding aberrant
development may hold lessons for cancer (21). Malignant trans-
formation of cells typically involves dedifferentiation, reactivation of
developmental pathways, and phenotypic plasticity. PIK3CAH1047R
was recently linked to induction of multipotency and cellular
dedifferentiation in two mouse models of breast cancer (8, 16).
Overexpression of wild-type (WT) PIK3CA in the head and neck
epithelium of a mouse model of oral carcinogenesis has also been
associated with dedifferentiation and epithelial-to-mesenchymal tran-
sition, increased transforming growth factor β (TGFβ) signaling,
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and up-regulated expression of the pluripotency factorsNanog and
Pou5f1 (Oct3/4) (22). Despite the insights gained from these and
other mouse models of oncogenic PIK3CA, efforts to establish in
vivo models of PROS have highlighted that species differences
may constrain extrapolation from model organisms to the mech-
anisms of pathological PI3K activation in human disease (5).
Due to their unlimited self-renewal and differentiation ca-
pacity, human pluripotent stem cells (hPSCs) are increasingly
used as tools to develop more relevant human disease models
(23). Their inherent similarities to cancer cells also make them
an attractive system in which to study oncogenic processes (24).
Thus, to study dose-dependent effects of pathological PI3K
hyperactivation in a developmental system of relevance to cancer
and PROS, we engineered isogenic human induced pluripotent
stem cells (iPSCs) to express PIK3CAH1047R from one or both
endogenous loci. Our data reveal clear dose-dependent de-
velopmental phenotypes downstream of p110α activation, with
homozygosity but not heterozygosity for PIK3CAH1047R pro-
moting self-sustained stemness in vitro and in vivo. These find-
ings emphasize the importance of using precisely engineered
models of cancer-associated PIK3CA variants to obtain a faithful
representation of their biological effects and have implications
for our understanding of PI3K activation in human disease.
Results
Generation of Human iPSCs with Endogenous Expression of PIK3CAH1047R.
To establish a cell model suitable for interrogation of allele dose-
dependent consequences of p110α activation in human develop-
ment and disease, we used CRISPR/Cas9 genome editing of well-
characterized, karyotypically normal WT iPSCs to generate mul-
tiple isogenic clones either heterozygous (n = 3) or homozygous
(n = 10) for the activating PIK3CAH1047R allele (SI Appendix, Fig.
S1 A–C). To control for nonspecific effects caused by genetic
drift following so-called bottleneck selection (25, 26), we ex-
panded six WT clones exposed to the gene-targeting process.
Sequencing of multiple clones of each genotype showed no evi-
dence of mutagenesis of 17 computationally predicted CRISPR
off-target sites (SI Appendix, Fig. S1D), and a normal karyotype
was confirmed in three homozygous and two heterozygous clones
more than 10 passages after targeting (SI Appendix, Fig. S1E).
WT and PIK3CAWT/H1047R colonies had a similar microscopic
appearance, whereas PIK3CAH1047R/H1047R clones exhibited ab-
errant colony morphology, characterized by disorganization of
the normal epithelial appearance, including pronounced F-Actin-
rich protrusions visible on colony margins (Fig. 1). Homozygous
cells also proved more adherent in routine passaging, requiring
longer dissociation time than WT and heterozygous cultures.
Nevertheless, PIK3CAH1047R/H1047R clones remained positive for
the pluripotent stem cell markers NANOG, OCT3/4, and TRA-1-
60 (Fig. 1), consistent with preserved stem cell identity.
Allele Dose-Dependent Signaling Effects of PIK3CAH1047R. We next
assessed PI3K signaling in PIK3CAWT/H1047R and PIK3CAH1047R/H1047R
iPSCs. p110α protein expression was reduced in both mutant
genotypes and sometimes barely detectable in PIK3CAH1047R/H1047R
cells. Despite this, immunoblotting revealed graded increases in AKT
phosphorylation across PIK3CAWT/H1047R and PIK3CAH1047R/H1047R
lines, both in growth factor-replete conditions (Fig. 2A) and upon
growth factor removal (Fig. 2B). Consistent with previous findings in
breast epithelial cells heterozygous for PIK3CAH1047R (19), both
PIK3CAWT/H1047R and PIK3CAH1047R/H1047R cells also showed modest
and graded increases in ERK phosphorylation.
Baseline PI3K pathway hyperactivation was inhibited in a
dose-dependent manner by the p110α-specific inhibitor BYL719,
while the p110β-specific inhibitor TGX221 had no effect (Fig.
2C). BYL719 did not reverse the allele dose-dependent down-
regulation of the p110α protein, suggesting that it is not caused
by acute negative-feedback mechanisms. In both mutant geno-
types, low-dose BYL719 (100 nM) reduced AKT phosphoryla-
tion to the level in untreated WT cells (Fig. 2C), without
inhibiting growth (SI Appendix, Fig. S2A). Relative to WT controls,
mutant stem cells exhibited increased survival upon prolonged
growth factor depletion, and this was also reversed by low-dose
BYL719 (SI Appendix, Fig. S2B). A higher concentration of
BYL719 (500 nM) was cytotoxic to both WT and PIK3CAWT/H1047R
cells (SI Appendix, Fig. S2A), but not PIK3CAH1047R/H1047R cells, in
which it reversed the aberrant colony morphology (SI Appendix,
Fig. S2 A and C).
We also examined responses to acute stimulation with insulin,
insulin-like growth factor 1 (IGF1), or epidermal growth factor
(EGF) (Fig. 2D). PIK3CAWT/H1047R and PIK3CAH1047R/H1047R
cells had high baseline AKT phosphorylation. This exceeded the
level in IGF1-stimulated WT cells, but no consistent increase in
the response to IGF1 was seen in mutant cells compared with
WT (Fig. 2D). Insulin did not elicit discernible AKT phosphory-
lation in any of the iPSC cells used. This apparent insulin resistance
may be caused by the high concentration of insulin (3 μM) used in
the maintenance medium (27), resulting in down-regulation of in-
sulin receptor expression at the plasma membrane (28). A modest
increase in AKT phosphorylation in response to EGF was only
Fig. 1. Isogenic hPSCs expressing PIK3CAH1047R from
one or both endogenous alleles. Representative light
microscopy and immunofluorescence images of stem
cell colonies from cultures with the indicated geno-
types. F-Actin staining was used to visualize cell shape,
and arrows highlight altered edge morphology and F-
Actin–rich protrusions in PIK3CAH1047R/H1047R colonies.
(Scale bars: 400 μm; Insets, 50 μm.) Light micrograph
images are representative of multiple clones from
each genotype (4 WT, 3 PIK3CAWT/H1047R, and 10
PIK3CAH1047R/H1047R). The confocal images are of WT
and mutant cells stained with antibodies against
OCT3/4, NANOG, and TRA-1-60. Images are repre-
sentative of at least two independent experiments
and clones per genotype. (Scale bar: 100 μm.) See also
SI Appendix, Fig. S1.
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observed in homozygous mutant cells. In contrast, EGF stimu-
lation enhanced ERK phosphorylation above baseline in all iPSC
lines, and this was progressively enhanced across heterozygous
and homozygous mutant cells (Fig. 2D). These findings suggest
that the MAPK/ERK pathway is primed to hyperrespond to
growth factor stimulation in PIK3CAH1047R stem cells, in an al-
lele dose-dependent manner.
Transcriptomic Effects of PIK3CAH1047R in Pluripotent Stem Cells. To
determine the wider dose-dependent consequences of genetic
p110α activation, we profiled the protein-coding transcriptome
of WT, PIK3CAWT/H1047R, and PIK3CAH1047R/H1047R iPSCs, cul-
tured in growth factor-replete conditions to mimic the in vivo
milieu of the pluripotent epiblast. Multidimensional scaling
demonstrated distinct transcriptomic signatures of WT, hetero-
zygous, and homozygous cells (Fig. 3A). The transcriptome of
PIK3CAWT/H1047R cells was nearly identical to WT controls, with
only 131 differentially expressed transcripts [false-discovery rate
(FDR), 0.05]. In contrast, homozygosity for PIK3CAH1047R led to
differential expression of 1,914 genes (Fig. 3A). This indicates
widespread transcriptional remodeling with a sharp allele dose
dependency, suggestive of a threshold effect.
Kyoto Encyclopedia of Genes and Genomes annotation-based
pathway analysis using all 1,914 differentially expressed genes in
PIK3CAH1047R/H1047R cells demonstrated significant changes to
PI3K/AKT signaling, as expected. “Pathways in cancer” was iden-
tified as a common central node, highlighting the power of our
isolated genetic activation of PI3K to recapitulate signatures iden-
tified in the genetically far more chaotic context of tumors (SI
Appendix, Fig. S3). Other pathways identified as showing coherent
perturbations were “Extracellular matrix-receptor interaction”
and “Focal adhesion,” in keeping with the altered morphology
and adhesion properties of homozygous mutants. Several genes
involved in pluripotency regulation and WNT signaling were also
differentially expressed. Finally, the TP53 pathway was found to
be significantly altered (SI Appendix, Fig. S3). This is consistent
with prior evidence of TP53 activation in cell lines with hyper-
activation of PI3K/AKT (29–32). However, given the recent re-
port that a substantial proportion of iPSC lines have TP53
mutations (33), we sequenced the TP53 gene of all clones. We
found that two of the WT lines were indeed heterozygous for
TP53 C135F (SI Appendix, Fig. S4A), a mild loss-of-function allele
based on biochemical assays in yeast (34). Despite this, inspection
of each iPSC clone’s RNA-seq data for the differentially expressed
A B
C D
Fig. 2. Graded activation of PI3K signaling in PIK3CAH1047R hPSCs. Immunoblots are shown for p110α and p110β catalytic subunits of PI3K, and for total and
phosphorylated AKT (S473) and ERK1/2 (T202/Y204; T185/Y187), with Coomassie-stained gels after transfer as loading control. Numbers below bands indicate
quantification by densitometry (arbitrary units). (A) Signaling in cells collected 3 h after replenishment of growth factor (GF)-replete medium. Representative
of at least three independent experiments. (B) Signaling time course during short-term GF depletion. Representative of at least two independent experi-
ments. (C) Effects of 24 h of specific p110α or p110β inhibition in GF-replete medium using BYL719 or TGX221, respectively. DMSO (D) was used as control.
Representative of two independent experiments. (D) Response of cells to 2 h of GF depletion followed by 20-min stimulation with 10 nM insulin (INS), insulin-
like growth factor 1 (IGF1), or epidermal growth factor (EGF). GF-free DMEM/F12 medium (M) was used as control. The results are representative of two
independent experiments. In all cases, independent clones of the same genotypes were used for replicate experiments. Protein pool dilutions are included
where possible to assess assay performance (numbers represent micrograms). WT, wild type; HET, PIK3CAWT/H1047R; HOM, PIK3CAH1047R/H1047R. See also SI
Appendix, Fig. S2.
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TP53 signaling genes showed that the signature difference in
PIK3CAH1047R/H1047R cells was not attributable to these two WT lines.
To identify potential drivers of the transcriptional changes in
PIK3CAH1047R/H1047R cells, we also undertook Ingenuity pathway
analysis of upstream regulators. This again revealed the expected
activation of PI3K/AKT signaling. It also implicated factors im-
portant in stem cell regulation, including TGFβ, FGF2, TP53,
β-catenin, and MYC (Fig. 3B). TGFβ was the most significant
prediction, and supporting increased signaling within this pathway,
we found increased phosphorylation of SMAD2 in homozygous
mutants (SI Appendix, Fig. S4B). These cells also had up-regulated
expression of NODAL (Fig. 3C and SI Appendix, Fig. S3), a
member of the TGFβ superfamily that maintains the pluripotent
epiblast at early developmental stages and later induces prim-
itive streak formation during gastrulation (35). Consistent with
NODAL’s dual function, PIK3CAH1047R/H1047R cells exhibited a
stemness signature (36) including up-regulation of NANOG,
POU5F1 (OCT3/4), MYC, KDR, IGF1R, as well as up-regulation
of primitive streak markers such as FGF4, GDF3, and FOXA2
(Fig. 3C and SI Appendix, Fig. S3). Up-regulation of NODAL in
WT and mutant cells was abolished by p110α-specific inhibition
with BYL719 (SI Appendix, Fig. S4C). In comparison, NANOG
expression remained mostly unaffected by BYL719, with a
trend toward down-regulation after 48 h of p110α inhibition (SI
Appendix, Fig. S4C). These findings suggest up-regulation of
NODAL and enhanced TGFβ/SMAD2 signaling as a candidate
C
A
B
Fig. 3. Widespread transcriptional remodeling in PIK3CAH1047R/H1047R pluripotent stem cells. (A, Left) Multidimensional scaling (MDS) plot of transcriptomes
of wild-type (WT), PIK3CAWT/H1047R (HET), and PIK3CAH1047R/H1047R (HOM) hPSCs profiled by RNA-seq. (A, Right) Venn diagrams showing overlap of up-
regulated and down-regulated transcripts in PIK3CAH1047R mutants compared with WT (FDR < 0.05, Benjamini–Hochberg; three clones per genotype). FC,
fold change. (B) Ingenuity pathway analysis (IPA) of upstream regulators in PIK3CAH1047R/H1047R cells, based on all differentially expressed genes. Components
with absolute activation z score > 2 and P < 0.05 are highlighted in red. Selected components linked to PI3K signaling and pluripotency are labeled. (C)
Assessment of expression of selected epiblast genes by real-time quantitative PCR, based on RNA-seq–specific pathway analyses. Data were obtained in two
independent experiments. Expression values were scaled to the WT (WT/WT) or PIK3CAH1047R/H1047R (H1047R/H1047R) mean as indicated. Individual points
correspond to separate cultures: five WT (three clones), three PIK3CAWT/H1047R (two clones), and six PIK3CAH1047R/H1047R (four clones). All clones used for
confirmation were distinct from those used to generate RNA-seq data. See also SI Appendix, Figs. S3 and S4.
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mechanism whereby p110α activation may exert effects on
stemness in hPSCs.
Homozygosity for PIK3CAH1047R Confers Self-Sustained Stemness upon
Embryoid Bodies. Embryoid bodies (EBs) are widely used to
model lineage specification during gastrulation (37, 38). Previous
studies have shown that NODAL overexpression in hPSC-
derived EBs blocks differentiation to all three germ layers
(39). Given the evidence for up-regulated NODAL and TGFβ
signaling in PIK3CAH1047R/H1047R cells, we tested whether the
resulting EBs would behave similarly to NODAL-overexpressing
EBs. EBs were established without TGFβ and FGF2, cultured in
suspension for 4 d, and allowed to generate adherent outgrowths
for 6 d (Fig. 4A). PIK3CAH1047R/H1047R stem cells consistently
generated compact, cystic EBs that failed to bud and undergo
internal reorganization (Fig. 4B), with notable resemblance to
mouse EBs overexpressing constitutively active PDK1 or AKT1
(40). In adherent culture, PIK3CAH1047R/H1047R EB outgrowths
resembled stem cell colonies (Fig. 4B). Confirming this, PIK3-
CAH1047R/H1047R EB outgrowths stained positive for the stemness
markers OCT3/4, NANOG, and TRA-1-60 (Fig. 4C). WT and
PIK3CAWT/H1047R EBs, in contrast, exhibited complex morphol-
ogies in suspension and yielded heterogeneous outgrowths of
differentiated cells, which continued to mature during the ex-
periment (Fig. 4 B and C).
The apparent differentiation block of PIK3CAH1047R/H1047R EBs
was assessed transcriptionally using lineage-specific arrays and can-
didate gene quantitative PCR. Unlike WT and PIK3CAWT/H1047R
EBs, homozygous mutants exhibited sustained expression of stem-
ness genes and failed to up-regulate germ layer-specific markers,
both in adherent cultures and in suspension (Fig. 4D and SI Ap-
pendix, Fig. S5 A–D). This phenotype persisted in the presence of
serum, which is used to induce EB differentiation (Fig. 4D and SI
Appendix, Fig. S5A). Attempts to reverse the PIK3CAH1047R/H1047R
EB phenotype with the p110α inhibitor BYL719 were unsuccessful
due to poor EB survival in the presence of the drug, consistent with
previous studies demonstrating high EB sensitivity to PI3K/mTOR
inhibition (40–42).
Heterozygosity for PIK3CAH1047R Is Compatible with Directed Definitive
Endoderm Formation. Heterozygosity for PIK3CAH1047R did not
produce major perturbations in the transcriptome of iPSCs nor in
EB differentiation. Nevertheless, observation of PIK3CA-driven
overgrowth in PROS suggests that mesodermal and neuro-
ectodermal tissues are widely involved, while tissues of endoder-
mal origin are only rarely affected by strong activating mutations,
raising the possibility of negative selection during endodermal
development (5). We thus sought to undertake more systematic
analysis of early differentiation in our human developmental
models of PIK3CAH1047R. To overcome the high variability seen in
A
B C
D
Fig. 4. Self-sustained stemness in PIK3CAH1047R/H1047R
embryoid bodies (EBs). (A) Schematic illustrating the
protocol used for EB formation and subsequent ad-
herent culture. E6, Essential 6 medium; FGF2, fibro-
blast growth factor 2; TGFβ, transforming growth
factor β. (B) Representative bright-field micrographs
of WT (WT/WT), PIK3CAWT/H1047R (WT/H1047R), and
PIK3CAH1047R/H1047R (H1047R/H1047R) cells at baseline
(iPSC stage), 4 d (suspension), 10 d (adherent), and 13 d
(suspension) following EB formation. PIK3CAH1047R/H1047R
iPSC colonies are refractile due to partial dissociation,
while stem cell-like colonies emerging from adherent
PIK3CAH1047R/H1047R EBs are highly compact. In addition
to the floating layers of differentiated cells shown here,
WT and PIK3CAWT/H1047R suspension cultures on day
13 also contained larger EB aggregates with complex
morphologies and internal differentiation. (Scale bar:
400 μm.) (C) EB outgrowths were fixed on day 10 and
stained for TRA-1-60 or costained for TUBB3/SOX17,
α-SMA/HAND1 or NANOG/OCT3/4. Hoechst was used for
nuclear visualization. Images are representative of two
independent experiments, using a single WT clone and
two clones of each mutant. (Scale bar: 100 μm.) (D) Real-
time quantitative PCR analysis of stemness gene ex-
pression in EB outgrowths in E6 medium without TGFβ
and FGF2. Individual replicates shown in the panel are
from three to four WT clones, two PIK3CAWT/H1047R
clones, and four PIK3CAH1047R/H1047R clones (including
technical duplicates of the PIK3CAH1047R/H1047R out-
growth cultures). Expression values are in arbitrary
units (A.U.). See also SI Appendix, Fig. S5.
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self-aggregating, spontaneously differentiating EBs, the protocol
was modified, incorporating use of microwell plates to ensure
homogeneous EB size (SI Appendix, Fig. S6A). EB formation was
followed by 3 d of exposure to different concentrations of Activin
A, BMP4, and FGF2 to promote mesoderm or definitive endo-
derm formation (43, 44). Lineage-specific gene expression arrays,
candidate gene quantitative PCR, and immunostaining assays
were used to assess expression of multiple differentiation markers.
Mesoderm or endoderm induction led to increased expression of
the expected lineage-specific markers (SI Appendix, Fig. S6 B and
C). The temporal pattern and relative expression levels of the
analyzed genes were similar for PIK3CAWT/H1047R and WT EBs
(SI Appendix, Fig. S6 B and C), and adherent outgrowths from both
stained positive for mesoderm and endoderm markers at the end of
the 10-d protocol (Fig. 5). The results of this assay argue against an
inability of PIK3CAWT/H1047R iPSCs to yield definitive endoderm.
We also subjected WT and PIK3CAH1047R-harboring cell lines
to monolayer-based directed differentiation using a combination
of low serum, inhibition of GSK3, and high levels of Activin A
(45) (Fig. 6A). The differentiation medium was also supplemented
with DMSO (control) or BYL719 (100 nM), in anticipation that
high PI3K signaling would be incompatible with 2D definitive en-
doderm formation, as reported previously (46, 47). Unexpectedly,
both PIK3CAWT/H1047R and PIK3CAH1047R/H1047R iPSCs differenti-
ated successfully to definitive endoderm under these directed
conditions, as evidenced by gene expression analysis and immu-
nostaining (Fig. 6B and SI Appendix, Fig. S7A). The dynamics of
gene expression were closely similar across the three genotypes
and were unaffected by p110α inhibition (Fig. 6B). Confirming
that this was not a donor-specific effect, similar results were
obtained with isogenic WT and mutant iPSCs derived from a
PROS patient with mosaic, heterozygous expression of the rare
PIK3CAE418K allele (SI Appendix, Fig. S7B).
Overall, these findings suggest that PI3K activation is compatible
with definitive endoderm formation in vitro, contrary to previous
conclusions based on the use of nonspecific pan-PI3K inhibitors with
known off-target effects (46, 47), and do not support cell-autonomous
negative selection in early endoderm specification in PROS.
Allele Dose-Dependent Effects of PIK3CAH1047R in Vivo. To confirm
that allele dose-dependent effects of PIK3CAH1047R were not
artifacts of in vitro culture, we injected immunodeficient mice
with WT or mutant iPSCs, and allowed them to form tumors
over 5–8 wk before histopathological assessment. WT and
PIK3CAWT/H1047R tumors contained differentiated components
of the three germ layers, including bone, cartilage, pigmented
epithelium, nervous tissue, and tubular endodermal structures
(Fig. 7A and SI Appendix, Table S1). All PIK3CAWT/H1047R tu-
mors exhibited better differentiated endoderm-derived tissues
including respiratory (all lines) and gastrointestinal (one line)
epithelium, corroborating the in vitro finding that heterozygosity
for PIK3CAH1047R does not impair definitive endoderm forma-
tion. In contrast, differentiated components were either com-
pletely absent or very immature in the two PIK3CAH1047R/H1047R
tumors (Fig. 7A and SI Appendix, Table S1), consistent with the
inability of the parental cells to yield spontaneously differenti-
ated EBs. The least mature of the PIK3CAH1047R/H1047R tumors
showed extensive recruitment of mouse stromal cells, forming
septae separating lobules of immature human tissue (SI Appen-
dix, Fig. S8A). Homozygous tumors also contained multiple foci
positive for T BRACHYURY (immature mesoderm) and nuclear
OCT3/4 (embryonal carcinoma marker in germ cell tumors) (SI
Appendix, Fig. S8 C and D). This was further confirmed by im-
munohistochemistry for another embryonal carcinoma marker,
CD30, which overlapped with OCT3/4-positive regions (SI Ap-
pendix, Fig. S8E). Additionally, PIK3CAH1047R/H1047R tumors
exhibited extensive necrosis and yolk sac-like tissue formation
(Fig. 7A and SI Appendix, Fig. S8 D and E and Table S1), the
latter suggested to be an in vivo characteristic of injected plu-
ripotent stem cells with malignant potential (48). These results
are in line with our in vitro studies and demonstrate that ho-
mozygosity but not heterozygosity for PIK3CAH1047R promotes
stemness of hPSCs.
Stem cells share many similarities with cancer cells, and phe-
notypes such as dedifferentiation and reactivation of develop-
mental pathways have been linked to epithelial-to-mesenchymal
transition and aggressive tumor behavior in vivo (49). PIK3CA
mutations in human tumors are not mutually exclusive with other
oncogenic alterations promoting PI3K pathway activation, sug-
gesting that further activation is positively selected for (50). This
raises the possibility that our findings may be relevant to un-
derstanding the behavior of human cancer. We thus analyzed the
prevalence of multiple oncogenic “hits” within the PI3K pathway
using data from The Cancer Genome Atlas (TCGA) on cancer
types with >10% prevalence of PIK3CA mutations. In aggregate,
21% of these cancers had PIK3CA mutations. Nearly 40% of this
subset had more than one copy of the mutation, and 25% also
had a mutation in other selected PI3K pathway components
(PTEN, PIK3R1, AKT1/2/3) or harbored a second PIK3CA variant
(Fig. 7 B and C). This high frequency of additional mechanisms
activating PI3K signaling in cancers provides circumstantial sup-
port for the notion that the strength of PI3K hyperactivation may
be important for tumor progression in vivo.
Discussion
We present a pluripotent stem cell model permitting assessment
of the consequences of selective genetic p110α activation spe-
cifically in a human developmental context. By using CRISPR-
mediated knockin of PIK3CAH1047R into one or both endogenous
PIK3CA alleles, we were able to examine the importance of mu-
tant PIK3CA allele dosage for pathway activation and downstream
cellular responses in human iPSCs. hPSCs are useful not only for
study of human embryogenesis but also of the effects of patho-
logical PI3K signaling, as seen in PROS and cancer cells (51). The
model we have generated may thus be useful for understanding
oncogenic actions of PIK3CAH1047R in different contexts. By using
expression from endogenous loci, by studying multiple clones of
each genotype, and by controlling for nonspecific variation in-
troduced during the targeting process, we have minimized analytic
Fig. 5. Heterozygosity for PIK3CAH1047R does not affect endoderm or me-
soderm differentiation in EBs. Representative confocal images of WT (WT/
WT) and PIK3CAWT/H1047R (WT/H1047R) outgrowths on day 10 of the dif-
ferentiation protocol, stained with antibodies against endoderm (AFP/
SOX17) and mesoderm (α-SMA/HAND1)-specific markers. Hoechst was used
for nuclear visualization and F-Actin for cell boundary demarcation. The
images are from one clone per genotype. (Scale bar: 100 μm.) See also SI
Appendix, Fig. S6.
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problems arising from overexpression of the gene of interest and
from nonspecific genetic and chromosomal abnormalities.
PIK3CAH1047R increased PI3K signaling “tone” both in growth
factor-replete and growth factor-depleted medium. Most strik-
ingly, we report distinct allele dose-dependent effects of mutant
PIK3CA on stemness and pluripotency in vitro and in vivo, with a
corresponding major alteration of the transcriptome triggered at
a threshold between heterozygous and homozygous p110α acti-
vation. At odds with our finding in human stem cells, heterozygous
expression of PIK3CAH1047R in a human MCF10A breast epithe-
lial cell line has previously been shown to cause widespread
transcriptional changes, illustrating the notion that small changes
in a nonlinear system can have extensive consequences (52, 53).
However, the mutant cells in these studies also had amplification
of chromosome 5p13-15 (53), a region harboring the gene
encoding the catalytic subunit of telomerase. This could have
contributed to the observed discrepancy to our study. Alterna-
tively, thresholds at which p110α signaling triggers its transcrip-
tional effects may differ among cell types. Exemplifying this,
either overexpression or endogenous expression of PIK3CAH1047R
induces multipotency in mammary tumors (8, 16), with the tumor
cell of origin dictating phenotypic severity.
The generation of human developmental cell models of
PIK3CAH1047R is also important given the well-documented dif-
ferences between the pathways regulating mouse and human stem
cell pluripotency and differentiation (54). Although we describe a
stem cell-based study focusing on endogenous expression of the
commonest pathogenic PIK3CA allele, several other studies have
adopted different strategies to activate other components of the
PI3K/AKT signaling cascade in this cell type (40, 55–58). Self-
sustained stemness is a common motif in the phenotypes repor-
ted, and some studies, like ours, argue for discernible PI3K dose
dependency. For example, mouse pluripotent stem cells with ho-
mozygous knockout of the isoform-agnostic type IA PI3K negative
regulator Pten exhibit impaired differentiation in vitro and in vivo,
but this is not seen in heterozygous knockout cells (57). How strong
PI3K activation sustains stemness remains to be determined; however,
our data suggest that induction of TGFβ signaling via NODAL is
likely to be important. Supporting this, several transcriptional changes
observed in PIK3CAH1047R/H1047R cells were reciprocal to those in
hPSCs exposed to pharmacological inhibition of TGFβ signaling
(59). It is also possible that the direct link between PI3K activation
and NODAL expression underlies the previously reported asso-
ciation between PI3K/AKT activation and expression of NANOG
(56, 60), a key pluripotency gene controlled by SMAD2/3 (61).
In contrast to the complex genetics of cancer, activating
PIK3CA mutations arise heterozygously and in isolation in the
A
B
Fig. 6. PIK3CAH1047R is compatible with monolayer definitive endoderm differentiation. (A) Schematic of the protocol for definitive endoderm differenti-
ation in monolayer culture. (B) Real-time quantitative PCR analysis of lineage marker expression during differentiation in the presence of DMSO (control) or
the p110α-specific inhibitor BYL719 at 100 nM. Data from two independent experiments (EXP) with WT (WT/WT) vs. PIK3CAH1047R/H1047R (H1047R/H1047R) are
shown side by side (60- and 84-h time points were only assessed once). Two cultures of each of two clones per genotype were profiled. The time course data
for PIK3CAWT/H1047R (WT/H1047R) vs. WT cells are from a single experiment using two cultures of one clone per genotype. Gene expression was scaled internally
to the mean value of an appropriate time point, and resulting values are arbitrary. B, baseline (0 h). See also SI Appendix, Fig. S7.
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severe overgrowth disorders known as PROS. An excess risk of
adult cancer has not been reported in these mosaic disorders, in
line with accumulating evidence that heterozygosity for PIK3CAH1047R
alone is not sufficient to cause cellular transformation (5). PROS
also illustrates the importance of controlled p110α signaling in
early human development. Overgrowth in PROS commonly af-
fects mesodermal and neuroectodermal lineages but rarely
endoderm-derived tissues, prompting speculation that a sus-
tained increase in PI3K activation impairs endoderm develop-
ment (5). It has also been reported that class IA PI3K signaling is
incompatible with directed definitive endoderm formation from
hPSCs, although this assertion is largely based on use of nonspecific
pan-PI3K inhibitors (46, 47). In our study, we found no evidence that
genetic PI3K activation impairs guided definitive endoderm forma-
tion in culture. Moreover, PIK3CAWT/H1047R pluripotent stem cells
gave rise to teratomas featuring well-differentiated endodermal
components, arguing against a cell-autonomous defect in endo-
derm specification as an explanation for overall lack of endoder-
mal overgrowth in PROS. The relatively mild biochemical and
transcriptional consequences of heterozygous PIK3CA activation in
stem cells, and their grossly normal early differentiation in several
different experimental contexts, suggest that any negative selection in
certain lineages may be exerted only at later stages of differentiation.
In contrast, homozygosity for PIK3CAH1047R in early development
will likely be selected against due to impaired differentiation and
embryonic lethality.
For all of the modesty of the cellular effects and lack of in-
creased adult cancer risk in PROS, we emphasize that hetero-
zygosity for PIK3CAH1047R is unequivocally causal in PROS,
reflecting the cumulative effects of sustained low-grade growth
promotion over an individual’s lifetime. The relatively small
signaling perturbation conferred by PIK3CAH1047R heterozygos-
ity, and the lack of cooperating lesions, makes treatment with a
low-dose p110α inhibitor a particularly promising option in this
setting. Consistent with this, low-dose BYL719 was shown re-
cently to produce highly clinically significant regression of
overgrowth in adults and children with PROS, without the side
effects associated with PI3K inhibition in cancer trials (62).
Our report of marked allele dose-dependent effects of PIK3CAH1047R
may also have implications for understanding of PI3K-associated
cancers. Many human cancers feature oncogenic alterations in
PIK3CA, and not only do these often occur with mutations in
other pathway components, but our data demonstrate the fre-
quent presence of more than one mutant PIK3CA copy, sug-
gesting that cancer cells benefit from additional PI3K pathway
activation. Future studies of the role of the PI3K pathway in
cancer progression should incorporate consideration of PI3K
signaling “dose” and the possibility of clear thresholds for bi-
ological consequences. Such considerations echo recent reports
that an increased dosage of mutant KRAS influences clinical
outcome and therapeutic targeting (63, 64). Supporting this
notion, Bielski et al. (65) also found that oncogene allelic im-
balances in human cancers were selected for through modest
dosage increases of gain-of-function variants, with consequences
for sensitivity to targeted therapy. Their study provides system-
atic evidence from human cancers against the commonly held
view that gain-of-function mutations in cellular oncogenes are
typically heterozygous, where a dominant mechanism of action is
thought sufficient to promote oncogenesis. Our genomic analy-
ses focusing on PIK3CA-associated cancers and oncogenic “hits”
within the PI3K pathway, combined with direct cellular evidence
of allele dose-dependent effects of PIK3CAH1047R, adds further
support to a revised oncogene model that takes into account the
functional implications of allelic imbalances. Based on these
observations, it will be interesting to determine whether cancers
with stronger activation of PI3K exhibit more aggressive features
A B
C
Fig. 7. PIK3CAH1047R allele dose-dependent effects in tumor xenografts and genetic evidence for graded PI3K activation in cancers. (A) Hematoxylin and
eosin (H&E)-stained sections of WT (WT/WT), PIK3CAWT/H1047R (WT/H1047R), and PIK3CAH1047R/H1047R (H1047R/H1047R) tumor xenografts derived from in-
jection of hPSCs into immunodeficient mice. The micrographs are from two tumors per genotype and are representative of totals of five, three, and two
tumors from WT, PIK3CAWT/H1047R, and PIK3CAH1047R/H1047R iPSCs, respectively. Yolk sac-like (YSL) and embryonal carcinoma-like (ECL) tissues, suggesting
neoplastic transformation of cells within the original cultures, were more prevalent in PIK3CAH1047R/H1047R tumors, which also exhibited extensive necrosis (N);
rare YSL foci were seen in two other tumors derived from the sameWT clone. The only well-differentiated tissue observed in PIK3CAH1047R/H1047R tumors was a
focus of immature bone (B) in one. WT and PIK3CAWT/H1047R tumors, in contrast, comprised variable admixtures of well-differentiated and organized tissue
derivatives of all three germ layers. GI, gastrointestinal tissue; mAT, mouse adipose tissue (confirmed by independent mouse vs. human immunostaining with
Cyclophilin A; SI Appendix, Fig. S8 A and B); PE, pigmented epithelium; RE, respiratory epithelium; SBLs, sebaceous-like tissue. See also SI Appendix, Fig. S8 and
Table S1. (B) The Cancer Genome Atlas (TCGA) was used to extract genomic data from PIK3CA-associated cancers. These were analyzed in aggregate for the
presence or absence of mutant PIK3CA alleles, followed by stratification of PIK3CAmutant-positive samples based on the presence of multiple mutant alleles,
including cases where the WT PIK3CA allele is lost (WT−). Alternatively, PIK3CAmutant-positive samples were screened for multiple distinct PIK3CAmutations
(*) or for the presence of additional mutations in proximal PI3K pathway components. (C) Schematic of proximal class IA PI3K signaling of relevance to the
analysis in B.
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such as a higher degree of dedifferentiation and metastatic po-
tential. Conversely, therapeutic sensitivity may also be higher in
tumors with increased PI3K signaling dose. Of note, a recent
clinical study evaluating the efficacy of AKT inhibition in patients
with the AKT1E17K mutation found frequent homozygosity for
this variant, and this was associated with a statistically and clin-
ically significant improvement in therapeutic response (66). As
the authors note, this may suggest that future patient stratifica-
tion for targeted cancer therapy should take into account the
tumor’s genomic configuration (66), including differences in oncogene
dosage and coincident oncogenic “hits” within the same pathway.
In summary, our study demonstrates that the cellular con-
sequences of the most common oncogenic PIK3CA mutation
are allele dose dependent. The observed near binary differ-
ences between PIK3CAH1047R heterozygosity and homozygosity
suggest that cells may have a PI3K signaling threshold that
determines the pathological consequences of this variant in
development and cancer. Prospective clinical studies are
needed to determine whether differences in the allele dosage of
activating PIK3CA mutations influence therapeutic outcomes
in cancer.
Methods
Additional information, including reagent catalog numbers and nucleic acid
sequences, are provided in SI Appendix.
Experimental Models. CRISPR/Cas9 targeting was performed on the male
WTC11 iPSC line line, a kind gift from Bruce Conklin (Gladstone Institutes and
University of California, San Francisco). The derivation of this line has been
described (67), and publicly available RNA, whole-exome, and whole-
genome sequencing data are available via the Conklin laboratory’s web-
site (https://labs.gladstone.org/conklin/wtc-information.html) or via the
Coriell Institute (GM25256). In the current work, the parental line was used
for gene editing at passage numbers P37 and P38. The derived iPSCs were
used for experiments between P45 and P60.
The PROS patient-derived iPSC lines M98-WT and M98-E418K were
obtained from a female, 18-y-old PROS patient by episomal reprogramming
of a dermal fibroblast culture with 32%mosaicism for PIK3CAE418K. All clones
used for experimental studies were confirmed transgene-free and expressed
high levels of PSC-specific markers, comparable to those of a reference hPSC
line. Karyotyping on a single line from each genotype confirmed lack of
microscopic genetic rearrangements. The original patient-derived dermal
fibroblasts were obtained with full informed consent in accord with the
Declaration of Helsinki. The study was approved by The Cambridge South
Ethics Committee (study reference no. 12/EE/0405).
CRISPR/Cas9 Targeting of Human iPSCs. TheWTC11 iPSC line was targeted with
plasmid-deliveredWT Cas9 (pX459; Addgene; 48139) and gBlock-encoded FE-
modified single guide RNAs (sgRNAs) (68). Targeting was performed by
nucleofection of 5 μg of pX459 plasmid (Cas9 WT), 3 μg of sgRNA-encoding
gBlock, and either 200-pmol targeting template (for homozygous tar-
geting) or a combination of 100-pmol targeting and “mock” templates
(for heterozygous targeting). The nucleofected cells were seeded into
Geltrex-coated 96-well plates and processed for sib-selection when ready
for passaging. Sib-selection was performed as described previously (69),
using 25–100 cells per well in each subcloning round. WT iPSC lines
obtained in the process of subcloning were banked as genetically
matched controls. Genotyping, including off-target assessment, by Sanger
sequencing and restriction fragment length polymorphism assays are
described in SI Appendix.
Differentiation Assays.
EBs. EBs were established either by spontaneous self-aggregation of hPSCs or
by forced aggregation into AggreWell plates. For self-aggregation, 50–70%
confluent hPSCs were dissociated into aggregates with ReLeSR, and the
entire cell suspension from a six-well transferred to one 60-mm Nunclon
Sphera ultra-low attachment dish in Essential 6 (E6) medium supple-
mented with 0.4% (wt/vol) polyvinyl alcohol (PVA) and RevitaCell
(E6/PVA+R). EBs formed within 24 h, after which the medium was exchanged
with E6 (without PVA and RevitaCell). The medium was exchanged again
on day 3 of EB formation. For adherent outgrowths, the EBs were trans-
ferred to Geltrex-coated six-well plates on day 4, either in regular E6 or in
E6 supplemented with 10% (vol/vol) FBS, 100 nM BYL719, or 0.01% (vol/
vol) DMSO. The EBs from a single Nunclon Sphera dish were used to seed
four wells of a 6-well plate or eight wells of a 12-well plate. EB outgrowths
were collected for RNA extraction on day 10 of EB formation. In one ex-
periment, suspension EBs were also collected on day 4 and day 13.
EB set-up in AggreWell plates followed the manufacturer’s instructions,
with E6/PVA+R as medium for cell seeding. A total of 2.4 × 105 cells was
seeded in each well, for a final density of 200 cells per microwell. EBs formed
within 24 h, and the contents of four to five individual wells were trans-
ferred to a single Nunclon Sphera ultra-low attachment dish for culturing in
either mesoderm (10 ng/mL BMP4, 5 ng/mL Activin A, 5 ng/mL FGF2) or
endoderm (0.25 ng/mL BMP4, 100 ng/mL Activin A, 2.5 ng/mL FGF2) in-
duction medium. After 3 d of induction, the EBs were transferred to Geltrex-
coated six-well plates for adherent growth and maintained in E6 until day
10. Cells were collected for RNA extraction on day 0 (iPSC stage), day 4, day
7, and day 10 of EB formation. For immunocytochemistry, day 4 EBs were
also seeded for adherent growth in Geltrex-coated four-well or 35-mm Ibidi
imaging dishes and processed for staining on day 10.
Definitive endoderm differentiation. Definitive endoderm differentiation of
iPSCs was carried out according to a modified version of the protocol de-
scribed in ref. 45. Further details are provided in SI Appendix.
Tumor Xenograft Assays. Tumor xenografts were generated from a total of
10 iPSC cultures (6 WT, 3 PIK3CAWT/H1047R, 2 PIK3CAH1047R/H1047R) by s.c. in-
jection into immunodeficient, male NSG mice (005557; The Jackson Labo-
ratory) at 12 wk of age. Individual animals were culled when tumors reached
∼1.4 cm3 in size, or if they became ill suddenly. All animal procedures were
performed with approval from the local Animal Welfare Ethical Review Body
and in accordance with Home Office regulations [The Animal (Scientific
Procedures) Act 1986].
Each tumor was processed for formalin fixation, paraffin embedding, mi-
crotome sectioning, and hematoxylin and eosin (H&E) staining as described in
ref. 70. The slides were analyzed blindly by a human pathologist and processed
for automated bright-field imaging on an AxioScan Z1 (Zeiss) slide scanner.
RNA Sequencing. A total of 1 μg of RNA per sample was used to synthesize
50-bp-long single-end mRNA libraries with an Illumina TruSeq Stranded
mRNA Library Prep Kit. The integrity and quantity of the libraries were
determined on the Bioanalyzer using the DNA 12000 Kit (Agilent). The
barcoded libraries were pooled and sequenced on an Illumina HiSeq
4000, with an average depth of 20 million reads per sample. The raw
reads were mapped to the human genome build GRCh38, and gene level
counts were determined using Spliced Transcripts Alignment to a Ref-
erence, version 2.5 (71). Subsequent data processing followed the
method outlined in ref. 72.
TCGA Data Analysis. The cancer genome analyses presented in this work are
based upon data generated by the TCGA Research Network: https://cancergenome.
nih.gov/. Somatic mutation tables (minor allele frequencies) from whole-
exome sequencing data across 11 cancer types (BLCA, BRCA, CESC, CRC,
ESCA, GMB, HNSC, LUSC, STAD, UCEC, and UCS) were downloaded from the
TCGA portal through the Genomic Data Commons Data Transfer Tool.
Mutation calls generated by Varscan2 (73) were used. To limit false posi-
tives, for those variants with a VAF (t_alt_count/t_depth) < 0.05, we
retained those that were also identified by the MuTect2 algorithm (74).
Functional annotation of genomic variants was performed with ANNOVAR
(75). Purity, ploidy, and copy number profiles of tumor cells were obtained
with ASCAT (76) run using default parameters on SNP6.0 data. For addi-
tional details, see SI Appendix.
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